Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Allo-HSCT for Mixed Phenotype Acute Leukemia

Haematologica; ePub 2017 Sep 29; Munker, et al

Publish date:: October 15, 2017

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) appears to benefit patients with mixed phenotype acute leukemia, according to a study involving 519 individuals. Participants—who were a median of ~38 years of age—had mixed phenotype acute leukemia in first complete remission and underwent allo-HSCT between 2000 and 2014. Approximately half were considered poor risk. Among the results:

Relapse rate at 3 years was 31%, and non-relapse mortality was 22%.
Leukemia-free survival rate was 47%, and overall survival was 56%.
One-third developed acute graft-versus-host disease (GVHD) at 6 months.
38% developed chronic GVHD at 3 years.
Age and year of transplant strongly predicted outcome.
Patients receiving myeloablative conditioning via total body irradiation tended to experience better leukemia-free survival.

Citation:

Munker R, Labopin M, Esteve J, Schmid C, Mohty M, Nagler A. Mixed phenotype acute leukemia: Outcomes with allogeneic stem cell transplantation, a retrospective study from the Acute Leukemia Working Party of the EBMT. [Published online ahead of print September 22, 2017]. Haematologica. doi:10.3324/haematol.2017.174441.

This Week's Must Reads

Phase II Trial of DNA Vaccine Encoding PAP in Patients with PCa ,

Utilization of Surgery for Post-prostatectomy Incontinence,

Claims Analysis of Advanced PCa Treatment Costs and Resource Use,

Testosterone Therapy Doesn't Increase Prostate Cancer Risk,

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced PCa,

Must Reads in AML

Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.

Venetoclax plus HMA studied in AML, DiNardo C et al. Blood. 2018 Oct 25. doi: 10.1182/blood-2018-08-868752.

T cell infusion effective in PML, Muftuoglu M et al. N Engl J Med. 2018 Oct 11;379:1443-51

Higher AML, MDS risk linked to autotransplants, Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7

Tibsovo for AML with IDH1 mutation, FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation, FDA press release